LX-2020 is under clinical development by Lexeo Therapeutics and currently in Phase II for Cardiomyopathy. According to GlobalData, Phase II drugs for Cardiomyopathy have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LX-2020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LX-2020 overview
LX-2020 is under development for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC). The therapeutic candidate comprises Adeno-associated virus (AAVrh10) vector delivering the gene that encodes plakophilin-2 (PKP2). It is administered by intravenous route.
Lexeo Therapeutics overview
Lexeo Therapeutics is a biotechnology company that is engaged in developing gene therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York, the US.
For a complete picture of LX-2020’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
